GENEWIZ (Suzhou Jinweizhi Biotechnology Co., Ltd.) was founded in 1999 and is headquartered in New Jersey, USA. It is a biotech company specializing in genome research and gene technology applications. Jin Weizhi provides high-throughput sequencing, Sanger sequencing, gene synthesis, primer synthesis, molecular biology services, and GLP standard specification services to scientific researchers worldwide. Based on Jin Weizhi's rigorous science and excellent services, many researchers, including nearly 30 Nobel laureates, have become loyal customers of Jin Weizhi. Many well-known multinational companies and universities around the world have also selected Jin Weizhi as their strategic partner and first choice supplier.

Anhui Wuyuan Chemical Group Co., Ltd., formerly known as Fuyang County Fertilizer Factory, was founded in 1970 and is located at No.1 Fukang Road, Yingdong District. It has now developed into a comprehensive chemical enterprise that integrates research and development, production, and sales. The company is currently a national high-tech enterprise with a provincial-level enterprise technology center. In 2007, Wuyuan Company and Shanxi Jincheng Anthracite Mining Group Co., Ltd. successfully implemented a joint venture cooperation, entering the fast lane of healthy development. The company currently has over 3200 employees and a total asset value of 8.258 billion yuan.

At present, Xinyi has become one of the industrial entities with the most complete product varieties and dosage forms in China. It has 11 major industrial enterprises, 2 major commercial companies, 1 procurement center, 1 municipal research and development center, and 2 joint ventures. It has nearly 1000 product approvals, covering 14 treatment fields, covering 20 dosage forms, and 2 national first-class new drug varieties. There are 405 product specifications in sales (of which 149 varieties and 270 product specifications have entered the latest national basic drug catalog, accounting for nearly half of the chemical basic drug catalog). On the basis of maintaining its competitive advantage in chemical preparations, Xinyi has also established a leading position in microecological preparations nationwide, as well as four characteristic dosage forms: aerosols, eye drops, soft capsules, and sustained-release preparations.

At present, Xinyi has become one of the industrial entities with the most complete product varieties and dosage forms in China. It has 11 major industrial enterprises, 2 major commercial companies, 1 procurement center, 1 municipal research and development center, and 2 joint ventures. It has nearly 1000 product approvals, covering 14 treatment fields, covering 20 dosage forms, and 2 national first-class new drug varieties. There are 405 product specifications in sales (of which 149 varieties and 270 product specifications have entered the latest national basic drug catalog, accounting for nearly half of the chemical basic drug catalog). On the basis of maintaining its competitive advantage in chemical preparations, Xinyi has also established a leading position in microecological preparations nationwide, as well as four characteristic dosage forms: aerosols, eye drops, soft capsules, and sustained-release preparations.

Hongqiao Pharmaceutical is a brand under Shanghai Hongqiao Pharmaceutical Co., Ltd. Shanghai Hongqiao Pharmaceutical Co., Ltd. was founded on March 30, 1982, with its main address at 7600 Zhongchun Road, Minhang District, Shanghai; Our main business includes retail of drugs, sales of medical devices (see license for details), thermometers, sphygmomanometers, magnetic therapy equipment, medical defatting gauze, medical hygiene masks, household blood glucose meters, blood glucose test strips, pregnancy diagnosis test strips (early pregnancy test strips), condoms, contraceptive caps, wheelchairs, medical sterile gauze, hardware and electrical appliances, cultural goods, general merchandise, cosmetics, food distribution, rental of self owned houses, business consulting (excluding brokers), warehousing management (excluding dangerous goods), and import and export of goods and technology. Wait. The nature of the company is limited liability company (invested or controlled by natural persons), with a registered capital of RMB 124.166296 million.

Shanghai Suhao Yiming Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Anke Biotechnology), established in 2001, is a high-tech enterprise mainly engaged in research, development, production, and sales of various GMP peptide raw materials and drugs. Experimental and production facilities with international advanced level: fully automatic peptide synthesis system, separation and purification system, freeze-drying system and other instruments and equipment. On the basis of introducing, digesting, and absorbing international advanced peptide synthesis production technology, we have established a leading high-tech platform for the large-scale research and development of active small molecule peptide drugs and precursors in China. We have independently developed a unique solid-phase synthesis process route suitable for industrial production, providing peptide preparation enterprises at home and abroad with highly cost-effective and high-quality peptide raw materials. At present, there are more than 40 peptide active pharmaceutical ingredients that have been listed or are in the clinical stage both domestically and internationally. The breadth and production of the products are leading in China. The company provides high-quality peptide products, peptide purification services, peptide synthesis reagents, and technical consulting services to users.